medigraphic.com
Instituto Nacional de Salud Pública

2020, Número 5

<< Anterior Siguiente >>

salud publica mex 2020; 62 (5)


La salud pública en la primera ola: una agenda para la cooperación ante Covid-19

Barrientos-Gutiérrez T, Alpuche-Aranda C, Lazcano-Ponce E, Pérez-Ferrer C, Rivera-Dommarco J

Idioma: Español
Referencias bibliográficas: 58
Paginas: 598-606
Archivo PDF: 269.40 Kb.


RESUMEN

El Covid-19 representa uno de los retos más grandes en la historia reciente de la salud pública. Es fundamental que se fortalezcan los lazos de cooperación científica bajo un objetivo común: proteger la salud de la población. En este artículo se presentan ideas que necesitan un desarrollo urgente y colaborativo. Se discute la estimación de la magnitud de la epidemia mediante un panel nacional de seroprevalencia y nuevas estrategias para mejorar el monitoreo en tiempo real de la epidemia. También se analizan las externalidades negativas asociadas con la respuesta a la pandemia. Finalmente, se presenta un marco general para el desarrollo de ideas para salir del confinamiento, resaltando la importancia de implementar acciones estructurales, sostenibles y equitativas. Se hace un llamado a la solidaridad y la cooperación, donde nuestros esfuerzos y creatividad se dediquen a la resolución de los problemas que enfrentan México y el mundo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization. Surveillance strategies for COVID-19 human infection. Interim guidance. No. WHO/2019-nCoV/National_ Surveillance/2020. Ginebra: WHO, 2020 [citado mayo 19, 2020]. Disponible en: https://www.who.int/publications-detail/surveillancestrategies- for-covid-19-human-infection

  2. Pan American Health Organization. Operational Guidelines for Sentinel Severe Acute Respiratory Infection (SARI) Surveillance. Washington: OPS, 2014.

  3. Lipsitch M, Donnelly CA, Fraser C, Blake IM, Cori A, Dorigatti I, et al. Potential biases in estimating absolute and relative case-fatality risks during outbreaks. PLoS Negl Trop Dis. 2015;9(7):1-16. https://doi.org/10.1371/ journal.pntd.0003846

  4. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample from Geneva, Switzerland. medRxiv. 2020. https://doi.org/10.1101/2020.05.02.20088898

  5. Gobierno de España. Estudio ENE-COVID19: primera ronda estudio nacional de sero-epidemiología de la infección por SARS-COV-2 en España. Madrid: Gobierno de España, 2020 [citado mayo 19, 2020]. Disponible en: https://www.ciencia.gob.es/stfls/MICINN/Ministerio/FICHEROS/ENECOVID_ Informe_preliminar_cierre_primera_ronda_13Mayo2020.pdf

  6. World Health Organization. Coronavirus disease (COVID-19) technical guidance: Unity Studies: Early Investigation Protocols. Ginebra: WHO, 2020 [citado mayo 15, 2020]. Disponible en: https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/technical-guidance/early-investigations

  7. Subramanian SV, James KS. Use of the Demographic and Health Survey framework as a population surveillance strategy for COVID-19. Lancet Glob Heal. 2020. https://doi.org/10.1016/S2214-109X(20)30213-8

  8. Méndez-Herrera A, Arias-Toledo E, Sánchez-Alemán M, Olamendi- Portugal ML, Ruiz-Gómez J, Díaz-Ortega JL. Prevalencia de anticuerpos frente a parotiditis en niños y adolescentes a dos años de haberse introducido la vacuna SRP. Salud Publica Mex. 2018;60(1):71-76. https:// doi.org/10.21149/8138

  9. Gobierno de España. Propuesta de diseño para llevar a cabo la encuesta sero-epidemiológica de la infección por SARS-COV-2 en España. Madrid: Gobierno de España, 2020 [citado mayo 15, 2020]. Disponible en: http:// cadenaser00.epimg.net/descargables/2020/04/06/9e8cf1112ff914621956e 1b519130636.pdf

  10. Kahn R, Kennedy-Shaffer L, Grad Y, Robins JM, Lipsitch M. Potential biases arising from epidemic dynamics in observational seroprotection studies. medRxiv. 2020. https://doi.org/10.1101/2020.05.02.20088765

  11. Medema G, Heijnen L, Elsinga G, Italiaander R, Brouwer A. Presence of SARS-Coronavirus-2 in sewage. medRxiv. 2020. https://doi. org/10.1101/2020.03.29.20045880

  12. World Health Organization. Coronavirus disease (COVID-19) technical guidance: Surveillance and case definitions. Ginebra: WHO, 2020 [citado mayo 15, 2020]. Disponible en: https://www.who.int/emergencies/ diseases/novel-coronavirus-2019/technical-guidance/surveillance-and-casedefinitions

  13. World Health Organization. Contact tracing in the context of COVID-19. Ginebra: WHO, 2020 [citado mayo 15, 2020]. Disponible en: https://www.who.int/publications-detail/contact-tracing-in-the-context-ofcovid- 19

  14. Allen D, Block S, Gostin L. Roadmap to Pandemic Resilience. Cambridge MA: Harvard University, 2020 [citado mayo 15, 2020]. Disponible en: https://ethics.harvard.edu/files/center-for-ethics/files/roadmaptopandemicresilience_ updated_4.20.20.pdf

  15. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020. https://doi.org/10.1001/jama.2020.8259

  16. Watson J, Whiting-Penny F BJE. Interpreting a covid-19 test result BMJ 2020. BMJ. 2020. https://doi.org/10.1136/bmj.m1808

  17. Gostic KM, Gomez ACR, Mummah RO, Kucharski AJ, Lloyd-Smith JO. Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19. Elife. 2020;9:e55570. https://doi.org/10.7554/ eLife.55570

  18. Kucirka LM, Lauer SA, Laeyendecker O, Boon D. Variation in falsenegative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020. https:// doi.org/10.7326/M20-1495

  19. Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert Rev Mol Diagn. 2020:20(5):453-4. https:// doi.org/10.1080/14737159.2020.1757437

  20. Weinberg CR. Making the Best Use of Test Kits for COVID-19. Am J Epidemiol. 2020. https://doi.org/10.1093/aje/kwaa080

  21. Peto J, Alwan NA, Godfrey KM, Burguess RA, Hunter DJ, Rioli E, Romer P. Universal weekly testing as the UK COVID-19 lockdown exit strategy. Lancet. 2020;395(10234);1420-1. https://doi.org/10.1016/S0140- 6736(20)30936-3

  22. Lou B, Li T, Zheng S, Su Y, Li Z, Liu W, et al. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. medRxiv. 2020. https://doi.org/10.1101/2020.03.23.20041707

  23. Altmann DM, Douek DC, Boyton RJ. What policy makers need to know about COVID-19 protective immunity. Lancet. 2020;6736(20):19-21. https://doi.org/10.1016/S0140-6736(20)30985-5

  24. Persad G, Emanuel EJ. The ethics of COVID-19 immunity-based licenses (“immunity passports”). JAMA. 2020. https://doi.org/10.1001/ jama.2020.8102

  25. Hall MA, Studdert DM. Privileges and immunity certification during the COVID-19 pandemic. JAMA. 2020. https://doi.org/10.1001/jama.2020.7712

  26. Bilal U, Barber S, Diez-Roux AV. Early evidence of disparities in COVID-19 Testing in US Cities. medRxiv. 2020. https://doi. org/10.1101/2020.05.01.20087833

  27. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Ginebra: WHO, 2020 [citado mayo 15, 2020]. Disponible en: https://www.who.int/docs/default-source/ coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf

  28. European Centre for Disease Prevention and Control (ECDC). Contact Tracing for COVID-19: Current Evidence, Options for Scale-up and an Assessment of Resources Needed. Suecia: ECDC, 2020 [citado mayo 15, 2020]. Disponible en: https://www.ecdc.europa.eu/sites/default/files/documents/ COVID-19-Contract-tracing-scale-up.pdf

  29. Li J, Guo X. COVID-19 contact-tracing apps: a survey on the global deployment and challenges. arXiv. 2020;1. Nueva York: Cornell University, 2020 [citado mayo 15, 2020]. Disponible en: http://arxiv.org/ abs/2005.03599

  30. Gorji H, Arnoldini M, Jenny DF, Hardt W-D, Jenny P. STeCC: smart testing with contact counting enhances Covid-19 mitigation by bluetooth 2 app based contact tracing. medRxiv. 2020. https://doi. org/10.1101/2020.03.27.20045237

  31. Instituto Nacional de Estadística y Geografía. Aviso COVID-19. México: INEGI, 2020 [citado mayo 18, 2020]. Disponible en: https://www.inegi.org. mx/default.html

  32. Legay A, Gala JL. Open Source Against COVID-19. Contact Tracing Apps. Leuven: Zenjoy, 2020 [citado mayo 15, 2020]. Disponible en: https:// www.opensourceagainstcovid19.org/es/

  33. Douglas M, Katikireddi SV, Taulbut M, McKee M, McCartney G. Mitigating the wider health effects of covid-19 pandemic response. BMJ. 2020;369:m1557. https://doi.org/10.1136/bmj.m1557

  34. Lai AG, Pasea L, Banerjee A, Denaxas S, Katsoulis M, Chang WH, et al. Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency. medRxiv. 2020. https://doi. org/10.1101/2020.05.27.20083287

  35. Gopalakrishnan A, Mossaid A, Lo KB, Vasudevan V, McCullough PA, Rangaswami J. Fulminant acute kidney injury in a young patient with novel coronavirus 2019. Cardiorenal Med. 2020:1-6. https://doi. org/10.1159/000508179

  36. Casini A, Fontana P, Glauser F, Robert-Ebadi H, Righini M, Blondon M. Risque thrombotique veineux induit par le SARS-CoV-2 : prévalence, recommandations et perspectives. Rev Med Suisse. 2020;16(692):951-4.

  37. Felix-Cardoso J, Vasconcelos H, Rodrigues P, Cruz-Correia R. Excess mortality during COVID-19 in five European countries and a critique of mortality analysis data. medRxiv. 2020. https://doi. org/10.1101/2020.04.28.20083147

  38. Faust J, del Rio C. Relative disease burdens of COVID-19 and seasonal influenza in New York City, February 1- April 18, 2020. medRxiv. 2020. https://doi.org/10.1101/2020.04.22.20073551

  39. Faust JS, del Rio C. The metric that could tell us when it’s safe to reemerge. The Washington Post, mayo 4, 2020 [citado mayo 15, 2020]. Disponible en: https://www.washingtonpost.com/opinions/2020/05/04/ metric-that-could-tell-us-when-its-safe-reemerge/

  40. Li J. Rehabilitation management of patients with COVID-19. Lessons learned from the first experiences in China. Eur J Phys Rehabil Med. 2020. https://doi.org/10.23736/S1973-9087.20.06292-9

  41. Lew HL, Oh-Park M, Cifu DX. The war on COVID-19 pandemic: role of rehabilitation professionals and hospitals. Am J Phys Med Rehabil. 2020. https://doi.org/10.1097/PHM.0000000000001460

  42. Wong LE, Hawkins JE, Langness S, Murrell KL, Iris P. Where are all the patients? Addresing Covid-19 fear to encourage sick patients to seek emergency care. Catalyst. 2020 [citado mayo 16, 2020]. Disponible en: https://catalyst.nejm.org/doi/full/10.1056/CAT.20.0193?query=C19#. Xr_1dBLpU44.twitter

  43. Omboni S. Telemedicine during the COVID-19 in Italy: a missed opportunity? Telemed e-Health. 2020. https://doi.org/10.1089/tmj.2020.0106

  44. Santoli JM, Lindley MC, DeSilva MB, Kharbanda EO, Daley MF, Galloway L, et al. Effects of the COVID-19 pandemic on routine pediatric vaccine ordering and administration — United States, 2020. MMWR. 2020;69(19):591-3. https://doi.org/10.15585/mmwr.mm6919e2

  45. Mongua-Rodríguez N, Hubert C, Ferreira-Guerrero E, de Castro F, Ferreyra-Reyes L, Villalobos-Hernández A, et al. Tendencias en las coberturas de vacunación en niños de 12 a 23 y 24 a 35 meses en México. Salud Publica Mex. 2019;61(6):809-920. https://doi.org/10.21149/10559

  46. Orcutt M, Patel P, Burns R, Hiam L, Aldridge R, Devakumar D, et al. Global call to action for inclusion of migrants and refugees in the COVID-19 response. Lancet. 2020. https://doi.org/10.1016/S0140- 6736(20)30971-5

  47. Platt L, Elmes J, Stevenson L, Holt V, Rolles S, Stuart R. Sex workers must not be forgotten in the COVID-19 response. Lancet. 2020. https:// doi.org/10.1016/S0140-6736(20)31033-3

  48. Bradbury-Jones C, Isham L. The pandemic paradox: The consequences of COVID-19 on domestic violence. J Clin Nurs. 2020. https://doi. org/10.1111/jocn.15296

  49. Volkow ND. Collision of the COVID-19 and Addiction Epidemics. Ann Intern Med. 2020. https://doi.org/10.7326/m20-1212

  50. Xie X, Xue Q, Zhou Y, Zhu K, Liu Q, Zhang J, et al. Mental health status among children in home confinement during the coronavirus disease 2019 outbreak in Hubei Province, China. JAMA Pediatr. 2020. https://doi. org/10.1001/jamapediatrics.2020.1619

  51. Ammar A, Trabelsi K, Brach M, Chtourou H, Boukhris O, Masmoud L, et al. Effects of home confinement on mental health and lifestyle behaviours during the COVID-19 outbreak: Insight from the “ECLB-COVID19” multi countries survey. medRxiv. 2020. https://doi. org/10.1101/2020.05.04.20091017

  52. Ammar A, Brach M, Trabelsi K, Boukhris O, Masmoudi L, Bouaziz B, et al. Effects of COVID-19 home confinement on physical activity and eating behaviour preliminary results of the ECLB-COVID19 international onlinesurvey. medRxiv. 2020. https://doi.org/10.1101/2020.05.04.20072447

  53. Roberton T, Carter ED, Chou VB, Stegmuller AR, Jackson BD, Tam Y, et al. Early estimates of the indirect effects of the COVID-19 pandemic on maternal and child mortality in low-income and middle-income countries: a modelling study. Lancet Glob Heal. 2020. https://doi.org/10.1016/S2214- 109X(20)30229-1

  54. Naja F, Hamadeh R. Nutrition amid the COVID-19 pandemic: a multilevel framework for action. Eur J Clin Nutr. 2020. https://doi.org/10.1038/ s41430-020-0634-3

  55. Frieden TR. A framework for public health action: The health impact pyramid. Am J Public Health. 2010;100(4):590-5. https://doi.org/10.2105/ AJPH.2009.185652

  56. Backholer K, Beauchamp A, Ball K, Turrell G, Martin J, Woods J, et al. A framework for evaluating the impact of obesity prevention strategies on socioeconomic inequalities in weight. Am J Public Health. 2014;104(10):e43-e50. https://doi.org/10.2105/AJPH.2014.302066

  57. Arias J. Coronavirus (Covid-19): con Ciclovía se descongestionará TransMilenio. Bogota.gov.co [citado mayo 16, 2020]. Disponible en: https:// bogota.gov.co/mi-ciudad/coronavirus-covid-19-con-ciclovia-se-descongestionara- transmilenio

  58. Karin O, Bar-On YM, Milo T, Katzir I, Mayo A, Korem Y, et al. Adaptive cyclic exit strategies from lockdown to suppress COVID- 19 and allow economic activity. medRxiv. 2020. https://doi. org/10.1101/2020.04.04.20053579




2020     |     www.medigraphic.com